BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack) vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack)
The complete healing triad combining the Wolverine Stack with GHK-Cu (copper peptide) for comprehensive tissue repair. This blend addresses healing at multiple levels: cellular repair, collagen synthesis, and tissue regeneration.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 & GHK-Cu (Triple Healing Stack) | Retatrutide |
|---|---|---|
| Mechanism | BPC-157 promotes angiogenesis and growth factor expression. TB-500 enhances cell migration and reduces inflammation. GHK-Cu activates genes involved in tissue remodeling, stimulates collagen and elastin production, and provides antioxidant protection. Together they support healing from multiple angles. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Typical protocol: BPC-157 250-500mcg daily, TB-500 2-2.5mg twice weekly, GHK-Cu 1-2mg daily or applied topically for skin applications. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | BPC-157 and TB-500 via subcutaneous injection. GHK-Cu can be injected subcutaneously or used topically depending on the target area. Systemic and local administration may be combined. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. Possible injection site irritation, mild fatigue, or temporary skin discoloration with GHK-Cu. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |